Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SRZN vs MTNB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: SRZN 3 – 2 MTNB (1 Tie) Matrix Metrics: SRZN 5 – 2 MTNB

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SRZN carries a Unified Composite Score of 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin), whereas MTNB carries 52.8/100 (HOLD) at $0.80 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (52.8/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs MTNB
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 73% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $30.47 · SMA50: $26.93
MTNB NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.80
-1.26% 1D
Market Cap $902,069
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -6.35β · 138% Vol
Unified Composite Score
52.8 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 32.8 · SMA20: $1.22 · SMA50: $1.48

6-Pillar Scorecard Institutional Category Breakdown (SRZN 3 – 2 MTNB)

Columns: Metric · SRZN · MTNB
1. Valuation Multiples SRZN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 52.1x N/M
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% -100.0%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $642.7M $902,069
3. Profitability & Quality MTNB
Gross Margin N/A N/A
Operating Margin -485.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -147.5%
4. Balance Sheet & Cash Flow MTNB
Cash Generation (TTM) -$31M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $1.2M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (13th %ile) N/A (N/A)
Put/Call OI Skew 21.00x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (5) vs MTNB (2)
Institutional Metric SRZN MTNB Criterion Row Edge
Market Capitalization
Scale
$642.7M $902,069 Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% -100.0% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% 0.0% Higher Margin MTNB
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -147.5% Higher ROE SRZN
52-Week Range Position
Momentum
63% ($13–$38) 22% ($0–$3) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.29β · 73% Vol -6.35β · 138% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 52.8 / 100 (HOLD) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 52.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) N/A ($1.2M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +63.74 pp
SRZN: +10.52% · MTNB: -53.22%
3M Horizon MTNB +288.34 pp
SRZN: +18.73% · MTNB: +307.07%
6M Horizon MTNB +5.68 pp
SRZN: +7.93% · MTNB: +13.61%
1Y Horizon SRZN +111.82 pp
SRZN: +110.81% · MTNB: -1.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue MTNB Revenue SRZN Op. Margin MTNB Op. Margin Margin Leader
FY2018 N/A $0M N/A -12230.9% MTNB
FY2019 N/A $0M N/A -21067.4% MTNB
FY2020 N/A $0M N/A -15288.4% MTNB
FY2021 N/A $0M N/A -74954.5% MTNB
FY2022 $10M $0M -354.7% -771.3% SRZN
FY2023 N/A $0M N/A -2168.4% MTNB
FY2024 $10M N/A -239.7% N/A SRZN
FY2025 $0M N/A -1210.6% N/A SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
41d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 13th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $902,069 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs MTNB Key Questions & Quantitative Answers

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SRZN carries a Unified Composite Score of 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin), whereas MTNB carries 52.8/100 (HOLD) at $0.80 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (52.8/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. -100.0% YoY).

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SRZN cumulative revenue shifted +0.0% while MTNB shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.

SRZN screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus MTNB (-147.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.35β · 138% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.